



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/567,630-Conf. #2853
Filing Date	May 30, 2006
First Named Inventor	Kari Alitalo
Art Unit	1634
Examiner Name	Kapushoc

Attorney Docket Number 28113/39467A

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A7	US-5,750,652	05-12-1998	Artavanis-Tsakonas et al.		
A8	US-5,780,300	07-14-1998	Artavanis-Tsakonas et al.		
A9	US-6,004,924	12-21-1999	Ish-Horowicz et al.		
A10	US-6,083,904	07-04-2000	Artavanis-Tsakonas		
A11	US-6,121,045	09-19-2000	McCarthy et al.		
A12	US-6,262,025	07-17-2001	Ish-Horowicz et al.		
A13	US-6,291,210	09-18-2001	Sakano et al.		
A14	US-6,380,362	04-30-2002	Watson et al.		
A15	US-6,433,138	08-13-2002	Zimrin et al.		
A16	US-6,436,650	08-20-2002	Artavanis-Tsakonas et al.		
A17	US-2003/0087807-A1	05-08-2003	Greenspan		
A18	US-2003/0224516	12-04-2003	Dobie		

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
B7	WO-00/06726		02-10-2000	Amgen, Inc.		
B8	WO-01/12664		02-22-2001	Chiron Corporation		
B9	WO-02/24221		03-28-2000	Genetech, Inc.		
B10	WO-03/027285		04-03-2003	Bionomics Ltd.		
B11	WO-03/047532		06-12-2003	Baylor College of Medicine		

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are subject under 37 CFR 1.98(e)(2)(ii) because the application was filed after June 30, 2003 or is available in the IWF. <sup>1</sup>Applicant's unique reference designation number (e.g., "Set 1" or "C-1") <sup>2</sup>Country of the Patent Office <sup>3</sup>Serial number of the Patent Document at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
C59	Kinzler et al., "Lessons from Hereditary Colorectal Cancer," <i>Cell</i> , 87, 159-170 (1996).		
C60	Loehla et al., "Lymphangiogenic Growth Factors, Receptors and Therapies," <i>Thrombosis and Haemostasis</i> , 90(2):167-184 (2003).		
C61	Maillard et al., "Notch and Cancer: Best to Avoid the Ups and Downs," <i>Cancer Cell</i> , 203-205 (2003).		
C62	Petrova et al., "Effects of Lymphatic Transcription Factor Prox-1 on Cell Cycle Progression," <i>J. Submicro. Cyt. Path.</i> , 32(3):406 (2000).		
C63	Wigle et al., "An Essential Role for Prox1 in the Induction of the Lymphatic Endothelial Cell Phenotype," <i>EMBO J.</i> , 21(7):1505-1513 (2002).		
C64	Xia et al., "siRNA-mediated Gene Silencing <i>in Vitro</i> and <i>in Vivo</i> ," <i>Nat. Biotech.</i> , 20(10):1006-1010 (2002).		

Examiner Signature	/Stephen Kapushoc/	Date Considered	01/12/2010
--------------------	--------------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/567,630-Conf. #2853
<i>(Use as many sheets as necessary)</i>				Filing Date	May 30, 2006
Sheet	2	of	2	First Named Inventor	Kari Alitalo
				Art Unit	1656 1634
				Examiner Name	Kapushoc
				Attorney Docket Number	28113/39467A

/STK/	C65	International Search Report for International Application No. PCT/EP2004/008819, mailed December 29, 2004.	
/STK/	C66	Written Opinion for International Application No. PCT/EP2004/008819, mailed December 29, 2004.	

<sup>1</sup>EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached

Examiner Signature	/Stephen Kapushoc/	Date Considered	01/12/2010
--------------------	--------------------	-----------------	------------